Scottsdale, AZ (PRWEB) July 01, 2012
QualityStocks would like to highlight International Stem Cell Corporation, a publicly traded company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs).
Seeking Alpha recently published the following article featuring International Stem Cell Corporation as one of the focus tickers: http://seekingalpha.com/article/693441
The article titled “Stem Cell Technology's Bright Future” labeled International Stem Cell Corp. as being possibly “the most promising” as the company has developed a breakthrough technology that provides pluripotent stem cells without using viable human embryos and without the issues associated with induced pluripotent stem cells or adult stem cells. Based upon unfertilized human eggs, the company's technology also allows superior immune-matching capabilities.
The idea behind stem cells has in fact been around for a very long time. Ever since the invention of the microscope and the development of cell theory, scientists have known that somehow the complex collection of specialized cells that make up the human body have their origin in a single fertilized egg. It was clear that, somewhere during the earliest stages of the developmental process, cells were being systematically transformed into specialized heart cells or nerve cells or liver cells or blood cells. The term “stem cell” was used as early as the late 1800s, before anything was really known about particular stem cells, but, by the early 1900s, it was recognized that different blood cells were all parented by a particular stem cell. By the early 1960s, there was a better understanding of the operation of bone marrow cells and the production of blood cells, which eventually led to today’s bone marrow transplants, the transplanting of adult stem cells for the treatment of leukemia and other blood related diseases.
As the technology to grow and work with human cells increased in the late 20th century, human stem cell research took off. Soon the first human embryonic stem cell lines were introduced, which scientists were able to use to fully establish the remarkable abilities of stem cells, suggesting their possible use in generating replacement cells for a broad range of tissues and organs. Since then, researchers have gained a deeper knowledge of the different types of stem cells, how to manipulate them, and the applications for which they can be most effectively used.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.